References
- Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
- Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diff use large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
- Hainsworth J D, Burris H A, III, Morrissey L H, Litchy S, Scullin Jr DC, Bearden J D, III, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 2000; 95: 3052–3056
- Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, et al. Tumor necrosis factor α release is a major biological event associated with rituximab therapy. Hematol J 2001; 2: 378–384
- Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006; 6: 407–409
- Wagner S A, Mehta A C, Laber D A. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82: 916–919
- Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. New Engl J Med 2003; 348: 2690–2691
- Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004; 91(Suppl 2)S18–S23
- Biehn S E, Kirk D, Rivera M P, Martinez A E, Khandani A H, Orlowski R Z, et al. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006; 24: 234–237
- Alexandrescu D T, Dutcher J P, O'Boyle K, Albulak M, Oiseth S, Wiernik P H. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 2321–2325
- Kanelli S, Ansell S M, Habermann T M, Inwards D J, Tuinstra N, Witzig T E. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001; 42: 1329–1337
- Byrd J C, Peterson B L, Morrison V A, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14
- Byrd J C, Peterson B L, Morrison V A, Park K, Jacobson R, Hoke E, et al. Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene. Eur Respir J 2002; 19: 912–918
- Van der Kolk L E, Grillo-López A J, Baars J W, Hack C E, van Oers M H. Complement activation plays a key role in the side-effects of rituximab therapy. Br J Haematol 2001; 115: 807–811
- Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224
- Sakao S, Tatsumi K, Igari H, Watanabe R, Shino Y, Shirasawa H, et al. Association of tumor necrosis factor-α gene promoter polymorphism with low attenuation areas on high-resolution CT in patients With COPD. Chest 2002; 122: 416–420
- Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski D E, et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS ONE 2006; 1: e108
- Leon R J, Gonsalvo A, Salas R, Hidalgo N C. Rituximab-induced pulmonary fibrosis. Mayo Clin Proc 2004; 79: 949–953
- Malik S W, Myers J L, DeRemee R A, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851–1856
- Cooper Jr JA, White D A, Matthay R A. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Repir Dis 1986; 133: 321–340